Form 4: Akero Therapeutics CEO Sells Shares to Cover Tax Obligations

Akero Therapeutics CEO Andrew Cheng sold 1,738 shares of common stock on September 10, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On September 10, 2024, Andrew Cheng, the President and CEO of Akero Therapeutics, sold 1,738 shares of Akero Therapeutics, Inc. common stock.
• The sale was executed at a price of $26.18 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Andrew Cheng directly owns 605,417 shares of Akero Therapeutics common stock.
• The sale was automatic and not at the discretion of the Reporting Person, according to the document.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sell-to-cover) and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is a common practice to cover tax obligations.

Key Dates